Cigna gets outcomes-based discounts for PCSK9s

Cigna Corp. (NYSE:CI) said Wednesday that it signed outcomes-based pricing contracts covering cholesterol-lowering PCSK9 drugs Praluent alirocumab and Repatha evolocumab. Cigna said the contracts include a negotiated price, provided patients using the drugs meet or exceed "expected LDL-C reduction." If patients are unable to reduce LDL-C "at least as well as what was experienced in clinical trials," then Cigna said it will receive a further discount.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) market Praluent. Amgen Inc. (NASDAQ:AMGN) markets Repatha. ...